By Dean Seal


Pfizer Inc. said the Phase 3 trial studying its drug Talzenna as a treatment for metastatic castration-resistant prostate cancer reached its primary endpoint, with significant improvement shown in radiographic progression-free survival.

The trial compared the use of Talzenna and Xtandi, another of Pfizer's prostate cancer medications, with the use of a placebo and Xtandi.

Pfizer said Tuesday that results showed a trend toward improved overall survival, which was a key secondary endpoint, though the company noted that the data were not yet mature at the time of analysis. Other secondary endpoints are still being analyzed.

Detailed results will be submitted for presentation at a near-term medical congress, Pfizer said.


Write to Dean Seal at


(END) Dow Jones Newswires

October 04, 2022 07:30 ET (11:30 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 11 2022 まで 12 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 12 2021 まで 12 2022 Pfizerのチャートをもっと見るにはこちらをクリック